|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 44, 2039-2048, November 2003
Copyright © 2003 by American Society for Biochemistry and Molecular Biology

* Discovery Research, CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304
Pharmacological Sciences, CV Therapeutics, Inc., 3172 Porter Dr., Palo Alto, CA 94304
1 To whom correspondence should be addressed. e-mail: jeffrey.chisholm{at}cvt.com
Liver X receptor (LXR) ligands are currently being evaluated as potential therapeutic agents for the treatment of low HDL. The LXR ligand T0901317 elevates ATP binding cassette transporter A1 (ABCA1) and HDL levels in animal models and induces moderate lipogenesis through upregulation of sterol regulatory element binding protein 1c (SREBP1c). Because insulin may also regulate lipogenesis through SREBP1c and fatty acid synthase (FAS), we investigated the effect of an LXR ligand in hyperinsulinemic mice. Administration of T0901317 to male db/db mice for 12 days resulted in a more severe hypertriacylglycerolemia and hepatic triacylglycerol accumulation than observed in nondiabetic mice. The LXR target genes ABCA1, SREBP1c, FAS, and stearoyl-CoA desaturase 1 were upregulated by T0901317 treatment in both diabetic db/db and nondiabetic C57BLKS mice. Changes in lipogenic gene expression were independent of mouse strain, indicating that the severe lipogenesis observed in LXR ligand-treated db/db mice was not due to additive effects of insulin on lipogenic gene expression. Phosphoenolpyruvate carboxykinase expression was suppressed, suggesting that a shift from gluconeogenesis toward lipogenesis could partially explain our observations in db/db mice.
Our data suggest that LXR ligands that have effects on both fatty acid and carbohydrate metabolism should be carefully evaluated in obesity, insulin, and leptin resistance.
Supplementary key words liver X receptor leptin receptor ATP binding cassette transporter A1 very low density lipoprotein triglycerides triacylglycerols diabetes atherosclerosis db/db
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. Smoak, J. Madenspacher, S. Jeyaseelan, B. Williams, D. Dixon, K. R. Poch, J. A. Nick, G. S. Worthen, and M. B. Fessler Effects of Liver X Receptor Agonist Treatment on Pulmonary Inflammation and Host Defense J. Immunol., March 1, 2008; 180(5): 3305 - 3312. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Commerford, L. Vargas, S. E. Dorfman, N. Mitro, E. C. Rocheford, P. A. Mak, X. Li, P. Kennedy, T. L. Mullarkey, and E. Saez Dissection of the Insulin-Sensitizing Effect of Liver X Receptor Ligands Mol. Endocrinol., December 1, 2007; 21(12): 3002 - 3012. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Herzog, M. Hallberg, A. Seth, A. Woods, R. White, and M. G. Parker The Nuclear Receptor Cofactor, Receptor-Interacting Protein 140, Is Required for the Regulation of Hepatic Lipid and Glucose Metabolism by Liver X Receptor Mol. Endocrinol., November 1, 2007; 21(11): 2687 - 2697. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hashimoto, S. Matsumoto, M. Yamada, T. Satoh, and M. Mori Liver X Receptor-{alpha} Gene Expression Is Positively Regulated by Thyroid Hormone Endocrinology, October 1, 2007; 148(10): 4667 - 4675. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nilsson, K. Dahlman-Wright, C. Karelmo, J.-A. Gustafsson, and K. R. Steffensen Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter Nucleic Acids Res., July 10, 2007; (2007) gkm492v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Delvecchio, P. Bilan, K. Radford, J. Stephen, B. L. Trigatti, G. Cox, K. Parameswaran, and J. P. Capone Liver X Receptor Stimulates Cholesterol Efflux and Inhibits Expression of Proinflammatory Mediators in Human Airway Smooth Muscle Cells Mol. Endocrinol., June 1, 2007; 21(6): 1324 - 1334. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Beyea, C. L. Heslop, C. G. Sawyez, J. Y. Edwards, J. G. Markle, R. A. Hegele, and M. W. Huff Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol J. Biol. Chem., February 23, 2007; 282(8): 5207 - 5216. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Cha and J. J. Repa The Liver X Receptor (LXR) and Hepatic Lipogenesis: THE CARBOHYDRATE-RESPONSE ELEMENT-BINDING PROTEIN IS A TARGET GENE OF LXR J. Biol. Chem., January 5, 2007; 282(1): 743 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Talukdar and F. B. Hillgartner The mechanism mediating the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317 J. Lipid Res., November 1, 2006; 47(11): 2451 - 2461. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Chu, M. Miyazaki, W. C. Man, and J. M. Ntambi Stearoyl-Coenzyme A Desaturase 1 Deficiency Protects against Hypertriglyceridemia and Increases Plasma High-Density Lipoprotein Cholesterol Induced by Liver X Receptor Activation. Mol. Cell. Biol., September 1, 2006; 26(18): 6786 - 6798. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Proctor, T. Jiang, M. Iwahashi, Z. Wang, J. Li, and M. Levi Regulation of Renal Fatty Acid and Cholesterol Metabolism, Inflammation, and Fibrosis in Akita and OVE26 Mice With Type 1 Diabetes Diabetes, September 1, 2006; 55(9): 2502 - 2509. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Desvergne, L. Michalik, and W. Wahli Transcriptional Regulation of Metabolism Physiol Rev, April 1, 2006; 86(2): 465 - 514. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Albers, B. Blume, T. Schlueter, M. B. Wright, I. Kober, C. Kremoser, U. Deuschle, and M. Koegl A Novel Principle for Partial Agonism of Liver X Receptor Ligands: COMPETITIVE RECRUITMENT OF ACTIVATORS AND REPRESSORS J. Biol. Chem., February 24, 2006; 281(8): 4920 - 4930. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Loffler, M. Bilban, M. Reimers, W. Waldhausl, and T. M. Stulnig Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 797 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grefhorst, T. H. van Dijk, A. Hammer, F. H. van der Sluijs, R. Havinga, L. M. Havekes, J. A. Romijn, P. H. Groot, D.-J. Reijngoud, and F. Kuipers Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E829 - E838. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Kase, A. J. Wensaas, V. Aas, K. Hojlund, K. Levin, G. H. Thoresen, H. Beck-Nielsen, A. C. Rustan, and M. Gaster Skeletal Muscle Lipid Accumulation in Type 2 Diabetes May Involve the Liver X Receptor Pathway Diabetes, April 1, 2005; 54(4): 1108 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wang, B. Kurdi-Haidar, and J. F. Oram LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1 J. Lipid Res., May 1, 2004; 45(5): 972 - 980. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |